Literature DB >> 31698446

Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia.

Fares Alsawah1, Lydia Benitez2, Sarah Choi3, Bernard Marini2, Anthony Perissinotti2, Amy Skyles2, Patrick Burke4, Kristen Pettit4, Ashley Crouch4, Heather Fox4, Dale Bixby4.   

Abstract

Entities:  

Year:  2019        PMID： 31698446      PMCID： PMC6855106          DOI： 10.1182/bloodadvances.2019000289

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  12 in total

1.  Management of prolymphocytic leukemia.

Authors:  Claire Dearden
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

Review 2.  T-cell prolymphocytic leukemia.

Authors:  Amit Khot; Claire Dearden
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

3.  Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.

Authors:  Claire E Dearden; Amit Khot; Monica Else; Mike Hamblin; Effie Grand; Ashok Roy; Saman Hewamana; Estella Matutes; Daniel Catovsky
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

4.  Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.

Authors:  M J Dyer; G Hale; F G Hayhoe; H Waldmann
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

5.  Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

Authors:  R Pawson; M J Dyer; R Barge; E Matutes; P D Thornton; E Emmett; J C Kluin-Nelemans; W E Fibbe; R Willemze; D Catovsky
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

6.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

Authors:  C E Dearden; E Matutes; B Cazin; G E Tjønnfjord; A Parreira; B Nomdedeu; P Leoni; F J Clark; D Radia; S M Rassam; T Roques; N Ketterer; V Brito-Babapulle; M J Dyer; D Catovsky
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

7.  Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Authors:  M J Keating; B Cazin; S Coutré; R Birhiray; T Kovacsovics; W Langer; B Leber; T Maughan; K Rai; G Tjønnfjord; M Bekradda; M Itzhaki; P Hérait
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.

Authors:  G Hale; S Bright; G Chumbley; T Hoang; D Metcalf; A J Munro; H Waldmann
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

9.  A T-cell prolymphocytic leukemia case with central nervous system involvement.

Authors:  Umit Yavuz Malkan; Gursel Gunes; Okan Yayar; Haluk Demiroglu; Aysun Yesilirmak; Aysegul Uner
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report.

Authors:  Selçuk Göçmen; Murat Kutlay; Alev Erikçi; Cem Atabey; Ozkan Sayan; Aptullah Haholu
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831
View more
  3 in total

Review 1.  Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Jennifer L McNeer; Kjeld Schmiegelow
Journal:  Curr Hematol Malig Rep       Date:  2022-01-13       Impact factor: 3.952

2.  Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma.

Authors:  Susanne Jung; Jochen Greiner; Stephanie von Harsdorf; Pavle Popovic; Roland Moll; Jens Schittenhelm; Kosmas Kandilaris; Volker Daniel; Alexander Kunz; Michael Schmitt; Peter Dreger
Journal:  Blood Adv       Date:  2021-10-12

Review 3.  Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.

Authors:  Indumathy Varadarajan; Karen Ballen
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.